These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 30955858)

  • 41. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
    Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Personalising Treatment for High-Grade Serous Ovarian Carcinoma.
    Cojocaru E; Parkinson CA; Brenton JD
    Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):515-524. PubMed ID: 29934103
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dissecting the Role of SMYD2 and Its Inhibitor (LLY-507) in the Treatment of Chemically Induced Non-Small Cell Lung Cancer (NSCLC) by Using Fe
    Munawwar A; Sajjad A; Rasul A; Sattar M; Jabeen F
    Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513898
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
    Heinzelmann-Schwarz V; Knipprath Mészaros A; Stadlmann S; Jacob F; Schoetzau A; Russell K; Friedlander M; Singer G; Vetter M
    Gynecol Oncol; 2018 Jan; 148(1):79-85. PubMed ID: 29157627
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.
    Gitto SB; Whicker M; Davies G; Kumar S; Kinneer K; Xu H; Lewis A; Mamidi S; Medvedev S; Kim H; Anderton J; Tang EJ; Ferman B; Coats S; Wilkinson RW; Brown E; Powell DJ; Simpkins F
    Clin Cancer Res; 2024 Apr; 30(8):1567-1581. PubMed ID: 37882675
    [TBL] [Abstract][Full Text] [Related]  

  • 49. RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation.
    Cho HS; Hayami S; Toyokawa G; Maejima K; Yamane Y; Suzuki T; Dohmae N; Kogure M; Kang D; Neal DE; Ponder BA; Yamaue H; Nakamura Y; Hamamoto R
    Neoplasia; 2012 Jun; 14(6):476-86. PubMed ID: 22787429
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
    Wang W; Duan B; Zeng L
    Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
    Moschetta M; George A; Kaye SB; Banerjee S
    Ann Oncol; 2016 Aug; 27(8):1449-55. PubMed ID: 27037296
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
    Yan S; Xuan J; Brajanovski N; Tancock MRC; Madhamshettiwar PB; Simpson KJ; Ellis S; Kang J; Cullinane C; Sheppard KE; Hannan KM; Hannan RD; Sanij E; Pearson RB; Chan KT
    Br J Cancer; 2021 Feb; 124(3):616-627. PubMed ID: 33173151
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Histone methyltransferase SMYD2: ubiquitous regulator of disease.
    Yi X; Jiang XJ; Fang ZM
    Clin Epigenetics; 2019 Aug; 11(1):112. PubMed ID: 31370883
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Verticillin A Causes Apoptosis and Reduces Tumor Burden in High-Grade Serous Ovarian Cancer by Inducing DNA Damage.
    Salvi A; Amrine CSM; Austin JR; Kilpatrick K; Russo A; Lantvit D; Calderon-Gierszal E; Mattes Z; Pearce CJ; Grinstaff MW; Colby AH; Oberlies NH; Burdette JE
    Mol Cancer Ther; 2020 Jan; 19(1):89-100. PubMed ID: 31909733
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of the Substrate Specificity of the SMYD2 Protein Lysine Methyltransferase and Discovery of Novel Non-Histone Substrates.
    Weirich S; Schuhmacher MK; Kudithipudi S; Lungu C; Ferguson AD; Jeltsch A
    Chembiochem; 2020 Jan; 21(1-2):256-264. PubMed ID: 31612581
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.
    Gravells P; Neale J; Grant E; Nathubhai A; Smith KM; James DI; Bryant HE
    DNA Repair (Amst); 2018 Jan; 61():25-36. PubMed ID: 29179156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics.
    Franz A; Coscia F; Shen C; Charaoui L; Mann M; Sander C
    J Ovarian Res; 2021 Oct; 14(1):140. PubMed ID: 34686201
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers.
    Ciucci A; Zannoni GF; Buttarelli M; Lisi L; Travaglia D; Martinelli E; Scambia G; Gallo D
    Oncotarget; 2016 Feb; 7(7):8155-71. PubMed ID: 26797759
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.
    Yi J; Liu C; Tao Z; Wang M; Jia Y; Sang X; Shen L; Xue Y; Jiang K; Luo F; Liu P; Cheng H
    EBioMedicine; 2019 May; 43():225-237. PubMed ID: 30898650
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1.
    Baloch T; López-Ozuna VM; Wang Q; Matanis E; Kessous R; Kogan L; Yasmeen A; Gotlieb WH
    BMC Cancer; 2019 Jan; 19(1):44. PubMed ID: 30630446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.